Switching of Sildenafil to Riociguat in CTEPH Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

July 22, 2026

Study Completion Date

January 22, 2027

Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
DRUG

Riociguat (Adempas)

Oral riociguat administered according to established dose-adjustment scheme. Riociguat will be administered starting at at 1mg three times per day. If patient systolic blood pressure maintains at 95mmHg or higher, the dose will be increased 0.5mg every 2 weeks up to a maximum dose 2.5mg three times per day over 8-week period

Trial Locations (1)

Unknown

RECRUITING

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER